Teva Pharma (TEVA) Misses Q3 EPS by 6c
Get Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharma (NYSE: TEVA) reported Q3 EPS of $0.59, $0.06 worse than the analyst estimate of $0.65. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $4.03 billion.
GUIDANCE:
Teva Pharma reaffirms FY2021 EPS of $2.50-$2.70 and revenue of $16-16.4 billion.
For earnings history and earnings-related data on Teva Pharma (TEVA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PHINIA Inc. (PHIN) Reports Q1 EPS of $1.08, provides guidance
- HarborOne Bancorp, Inc. (HONE) Tops Q1 EPS by 6c
- Southern Copper Corp. (SCCO) Tops Q1 EPS by 20c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!